Aquestive Therapeutics, Inc.
General ticker "AQST" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $547.1M (TTM average)
Aquestive Therapeutics, Inc. does not follow the US Stock Market performance with the rate: -0.2%.
Estimated limits based on current volatility of 2.2%: low 3.92$, high 4.10$
Factors to consider:
- Total employees count: 147 (+3.5%) as of 2025
- US accounted for 69.4% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: FDA approval delays, Insufficient clinical data, Funding requirements, Third-party risks, Key executive retention
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [3.57$, 8.65$]
- 2026-12-31 to 2027-12-31 estimated range: [2.65$, 6.76$]
Financial Metrics affecting the AQST estimates:
- Positive: with PPE of -7.7 at the end of fiscal year the price was neutral
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Positive: Interest expense per share per price, % of 1.54 <= 3.34
- Positive: Industry inventory ratio change (median), % of 0.12 <= 0.28
- Positive: Investing cash flow per share per price, % of -0.08 > -0.60
Short-term AQST quotes
Long-term AQST plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $50.58MM | $57.56MM | $44.55MM |
| Operating Expenses | $65.69MM | $88.33MM | $114.20MM |
| Operating Income | $-15.10MM | $-30.77MM | $-69.65MM |
| Non-Operating Income | $7.48MM | $-13.38MM | $-14.13MM |
| Interest Expense | $6.56MM | $11.36MM | $11.36MM |
| R&D Expense | $13.10MM | $20.28MM | $17.19MM |
| Income(Loss) | $-7.62MM | $-44.15MM | $-83.78MM |
| Taxes | $0.24MM | $-0.01MM | $0.00MM |
| Net Income(Loss)* | $-7.87MM | $-44.14MM | $-83.78MM |
| Stockholders Equity | $-106.49MM | $-60.16MM | $-33.66MM |
| Inventory | $6.77MM | $6.04MM | $6.17MM |
| Assets | $57.42MM | $101.42MM | $160.43MM |
| Operating Cash Flow | $-6.38MM | $-35.76MM | $-52.43MM |
| Capital expenditure | $0.99MM | $0.16MM | $0.56MM |
| Investing Cash Flow | $-0.99MM | $-0.16MM | $-0.56MM |
| Financing Cash Flow | $3.97MM | $83.59MM | $102.62MM |
| Earnings Per Share** | $-0.13 | $-0.51 | $-0.69 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.